20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
about
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?20-year risk of breast cancer recurrence.Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.Major clinical research advances in gynecologic cancer in 2017.Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.Precision Medicine in Hormone Receptor-Positive Breast Cancer.Optimal management of luminal breast cancer: how much endocrine therapy is long enough?Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancerProfile of abemaciclib and its potential in the treatment of breast cancerCDK4/6 inhibition in breast cancer: current practice and future directionsEnrichment and detection of bone disseminated tumor cells in models of low tumor burdenSABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
P2860
Q47825566-6DA84F26-F139-40FD-825F-00D402192A18Q48238605-C9B17C59-75B3-4443-A0DB-6031DF1F732FQ48312267-35DB4AD5-EA42-43FE-85EB-A4AB895BA3B3Q48327802-CE0A8521-1078-4676-9DBF-143BDD7DB892Q53685792-615FEEA5-E167-440E-9CE5-20F799513A24Q54952356-6D50D5EE-92D1-4D91-AC47-CDBF9FE17D4BQ54987182-1DE5C39E-6574-4692-9AD6-E1FE5BB6DA82Q55379220-6134B2B1-DB29-4AE5-8981-A211AD834F67Q55424072-A1933269-AABE-4558-AAFB-A94E16E27EECQ55471424-707C7968-2A06-4A09-8787-143C5C8D906DQ56515226-7B1BAAEA-64CD-4D0A-9289-BD5129F091DAQ57107448-20B2B562-23AC-4095-9E2E-0DDC23E527E0Q57109486-A42AA5CF-D324-4B98-BE8B-064CD98F8113Q58700560-00DFDDA8-60CF-4E7C-82A8-1DC7275B9B20Q58726847-56A726D8-7B87-4A24-9D13-5FFBF1F880FA
P2860
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@en
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@nl
type
label
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@en
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@nl
prefLabel
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@en
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@nl
P2093
P2860
P50
P356
P1476
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
@en
P2093
Carolyn Taylor
Christina Davies
Daniel F Hayes
Hongchao Pan
Jeremy Braybrooke
Jonas Bergh
Kathleen I Pritchard
Paul McGale
Richard Peto
P2860
P304
P356
10.1056/NEJMOA1701830
P407
P577
2017-11-01T00:00:00Z